Keryx aims for dual listing on high-growth exchanges

27 Jul 2000

WESTLB and Roth Capital should complete the first simultaneous Nasdaq and Aim listing next week. The $46m-$55m IPO of Keryx Biopharmaceuticals was due to close on Tuesday, but has been postponed and will be completed imminently, a banker close to the deal said. The deal ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial